– UK, Eastleigh – Novacyt S.A. (LON: NCYT / EPA: ALNOV), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announced the immediate appointment of Dr. Ian Gilham as a Non-Executive Director to its board.
“It is a pleasure to welcome Ian to the Board of Novacyt. Ian has worked with a number of successful AIM-listed life sciences companies and we look forward to utilising his expertise as we further optimise and strengthen the Novacyt Group.” said CEO, Lyn Rees.
About Dr. Ian Gilham
Dr. Ian Gilham has a wealth of experience in AIM-listed life sciences companies, with an international track record in the research, development, and commercialization of diagnostic products that will further strengthen the expertise of the Novacyt Board. He currently holds roles as Non-Executive Chairman of AIM-listed Genedrive PLC, Chair of Trustees for LifeArc, a self-funded medical research charity, Non-Executive Chairman of Pelago Bioscience AB, a life sciences tools business based in Stockholm, and Non-Executive Chairman of RevoNA Bio, a University of Portsmouth spinout life sciences tools company. Ian has previously held Board positions at Aptamer Group PLC, Horizon Discovery PLC, Cytox Ltd, Elucigene Ltd, Multiplicom n.v, Biosufit s.a, Vernalis plc, Concepta Diagnostics Ltd, and was CEO of Axis-Shield PLC.
About Novacyt Group
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercializes molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health, and environmental.
For more: https://novacyt.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.